# Emory Vaccine and Treatment Evaluation Unit - KidCOVE

> **NIH NIH UM1** · EMORY UNIVERSITY · 2021 · $1,475,091

## Abstract

Narrative
The Emory VTEU will participate and enroll children into “A Phase 2/3, Two-Part, Open-Label,
Dose-Escalation, Age De-escalation and Randomized, Observer-Blind, Placebo-Controlled
Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of
mRNA-1273 SARS-CoV-2 Vaccine in Healthy Children 6 Months to Less Than 12 Years of Age
(KidCOVE)”.
1

## Key facts

- **NIH application ID:** 10382715
- **Project number:** 3UM1AI148576-02S2
- **Recipient organization:** EMORY UNIVERSITY
- **Principal Investigator:** EVAN J ANDERSON
- **Activity code:** UM1 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $1,475,091
- **Award type:** 3
- **Project period:** 2021-04-26 → 2023-02-28

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10382715

## Citation

> US National Institutes of Health, RePORTER application 10382715, Emory Vaccine and Treatment Evaluation Unit - KidCOVE (3UM1AI148576-02S2). Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/grant/nih/10382715. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*